← Leaderboards
Maria Palasis
Lyra Therapeutics, Inc.
$3,458,913
Attributed
$3,458,913
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2013–18$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$3,458,913 · 3
By mechanism
R44$2,860,961 · 1
N43$397,952 · 1
N01$200,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseDevicesSafetyDesignStentsCathetersSmall Business Innovation Research GrantNational Heart, Lung, And Blood InstituteClinical ResearchStenosisUnited StatesCommercializationArtery StenosisAwardPulmonary Artery StructureChildhoodMarketingFundingCharacteristicsLungChildImplantAccountingCardiovascular System
Grant awards (5)
Novel Bioabsorbable, Flexible Polymeric Stent for Pulmonary Artery Stenosis$925,951
R44 · FY2018 · HL · contact PI
Novel Bioabsorbable, Flexible Polymeric Stent for Pulmonary Artery Stenosis$945,564
R44 · FY2017 · HL · contact PI
Novel Bioabsorbable, Flexible Polymeric Stent for Pulmonary Artery Stenosis$989,446
R44 · FY2016 · HL · contact PI
IGF::OT::IGF SBIR TOPIC 096:THE DEVELOPMENT LEADING TO THE COMMERCIALIZATION OF A BIORESORBABLE STENTS (BRS) FOR THE TREATMENT OF COARCTATION OF THE AORTA IN NEONATES CAN# 16-8470256$397,952
N43 · FY2016 · HL · contact PI
IGF::OT::IGF SBIR Topic 079 Phase I- Bioabsorbable Stents for Pediatric Pulmonary$200,000
N01 · FY2013 · HL · contact PI